AliveDx is dedicated to expanding its reach and presence across diverse regions, with the goal of delivering both clinical and economical value to clinicians by reducing the time to diagnosis for patients suffering from autoimmune and allergy diseases.
We are thrilled to announce that we have multiple customers currently evaluating the MosaiQ system across the UK and Europe to see how this innovative solution can transform their labs.
The MosaiQ platform simplifies workflows and enhances efficiency through its advanced multiplexing microarray assay technology. This streamlined approach provides healthcare providers and patients with faster, more cost-effective diagnostic solutions.
With our innovative assay, IVDR CE-Marked AiPlex® CD for diagnosis of patients for Celiac Disease, AliveDx is also innovating and developing a robust pipeline of products targeting the diagnosis of Connective Tissue Diseases, and Allergies. These innovations aim to accelerate patient diagnoses, enabling treatments to begin sooner.
“This milestone represents another significant step toward the full commercialization of the MosaiQ solution and its assays, which are designed to empower diagnostic insights for laboratorians, transform patient care, and drive life-saving innovations” said Manuel O. Méndez, CEO of AliveDx.
Learn more about MosaiQ here.
